IPROOV
iProov , a leading provider of biometric facial verification technology, today announced it has become the first British – and indeed overseas – company to be awarded a contract from the US Department of Homeland Security Science & Technology Directorate’s Silicon Valley Innovation Program (SVIP).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180416006084/en/
The contract has been awarded to iProov to help US Customs and Border Protection (CBP) improve the passenger entry operation process.
London-based iProov was founded in 2011 by CEO Andrew Bud. The company’s facial biometric technology, patented in the US and UK, is used by banks and governments around the world for secure customer onboarding, logon and authentication, to ensure new and returning users are genuine and guard against fraudulent attempts to gain access to personal data or use a stolen identity.
The contract iProov has won will see the company develop technology that aims to enhance cross-border passenger travel at unmanned ports of entries while reducing processing time. It could help US CBP quickly, accurately and reliably identify travellers as they process through US border crossings.
At the heart of this announcement is iProov’s Flashmark technology, deployed in its secure, cloud-based facial biometric verification system that can be accessed via a user’s mobile phone. In this case, iProov’s technology will work with existing CBP systems, on which travellers’ details are pre-registered. In the run up to arrival at the US border, whether at home or en route, travellers would be able to self-serve the document check that normally happens at the point of border crossing, by authenticating themselves securely to their pre-registered photo, via their mobile phone. The process is simple, much quicker than waiting in line, and more secure than traditional methods.
Dr. Liam Fox, Secretary of State for the UK Department for International Trade, commented, “The UK and US are world leaders in cyber security. Through close cooperation across various sectors, trade between the two countries has grown to £181.2 billion pounds in 2017 - making the US our largest trading partner and biggest export market.
“One example of our shared economic and security ties is UK based iProov technology, which uses cutting-edge facial biometric verification technology to enhance security and deter those who seek to cause harm. It is now used by a range of institutions across the world and will soon be used by the US Customs and Border Protection, helping to enhance the way it processes people through US borders.”
The reason iProov was selected comes down to its ability to detect ‘spoofs’. In a self-serve identity verification environment, the system must be able to confirm whether or not the person presenting themselves for verification is genuinely the owner of the ID credential, not a photo, screen image or doctored video. iProov has ten granted patents in the UK and US for the technology that can detect these spoofs, and in this way is uniquely able to help governments tackle the pressure they are under from increased traveller numbers to swiftly but securely verify each and every traveller.
It is this growth in international travel which led the DHS S&T Directorate’s SVIP to look for partners to help tackle the cross-border passenger entry operation process. Over 112 million passengers enter the United States annually and over 1 million attempt to pass through its borders each day, increasing the pressure on Customs and Border Protection to facilitate the entry of international visitors, increase tourism and foster economic growth while ensuring the highest level of security.
iProov’s CEO, Andrew Bud, who will be speaking about the contract win while part of a UK trade delegation with the UK’s Department for International Trade to global cyber security conference RSA in San Francisco, commented, “We are delighted that iProov has been selected by the US Department of Homeland Security to enhance the way in which it processes people through US borders. Advances in machine learning and AI have enabled a revolution in facial biometrics in the last few years and we’re now seeing more and more cases of governments and banks turning to self-service, spoof-resilient face verification as the biometric of choice to both increase security and ensure ease of use.”
This is not the first time iProov has been recognised for its industry leading identity verification technology. The company won the 2017 National Cyber Security Centre’s Cyber Dragon’s Den competition at CYBERUK 2017; it has received a number of grants from Innovate UK, the UK's innovation agency; and in September 2017 was named the sole UK member of the SINET16, a select group of cyber-security innovators. In the financial services sector its technology is in live use with banks such as DNB in Norway and Rabobank in the Netherlands.
--ends--
About iProov
Founded in 2011 by CEO Andrew Bud, iProov is a world leader in spoof-resistant, biometric facial verification technology. Its technology is used by banks and governments around the world for secure customer onboarding, logon and authentication, to ensure new and returning users are genuine and guard against fraudulent attempts to gain access to personal data or use a stolen identity. For more information, please see www.iproov.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180416006084/en/
Contact:
IProov
Zoë Clark
Tyto
zoe.clark@tytopr.com
+44
7833 474 447
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom